Literature DB >> 23464468

Overexpression of her-2/neu in malignant mammary tumors; translation of clinicopathological features from dog to human.

Ahad Muhammadnejad1, Elahe Keyhani, Pejman Mortazavi, Farkhondeh Behjati, Iraj Sohrabi Haghdoost.   

Abstract

BACKGROUND: Canine mammary gland tumors (CMGTs) are the most common tumor found in bitches. Changes in HER-2/neu genes in human breast cancer (HBC) lead to decrease in disease-free survival (DFS) and overall survival rate (OSR). Previous studies have demonstrated that the biological behavior of malignant mammary gland tumors (MMGTs) is similar to that of HBC. The present study aimed at evaluating the relationship between overexpression of HER-2/neu and clinicopathological features in MMGTs to represent a model of prognostic factors for HBC. MATERIALS AND
METHOD: The clinicopathological data of 35 MMGTs were obtained. Immunohistochemical staining with HER-2, Ki-67 and CD34 markers was conducted with sections from paraffin-embedded blocks. According to standard protocols, histological type, grade, margin status, lymphovascular invasion (LVI), HER-2/ neu score, proliferation rate and microvessel density (MVD) of tumors were determined and the association of HER-2/neu overexpression with these parameters was assessed statistically.
RESULTS: The IHC results showed that 12 (34.3%) cases were HER-2/neu positive. Statistical analyses indicated a significant relationship between HER-2 positivity and tumor grade (p=0.043), which also was demonstrated with cancer stage (p=0.035), tumor margin involvement (p=0.016), proliferation index (p=0.001) and MVD (p=0.001); however, there was no statistical relationship between LVI and tumor size. Overexpression of the HER-2/neu gene in MMGTs results in similar biological behavior as that of HBC; as a result, these tumors have can be considered to have important similarities in clinicopathological characteristics.
CONCLUSIONS: MMGTs can be regarded as an HBC animal model. Further studies in this field would result in new treatments that could be beneficial for both dogs and humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23464468     DOI: 10.7314/apjcp.2012.13.12.6415

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  10 in total

1.  Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer?

Authors:  G P Burrai; A Tanca; M R De Miglio; M Abbondio; S Pisanu; M Polinas; S Pirino; S I Mohammed; S Uzzau; M F Addis; E Antuofermo
Journal:  Tumour Biol       Date:  2015-06-19

2.  Expression of vimentin filaments in canine malignant mammary gland tumors: A simulation of clinicopathological features of human breast cancer.

Authors:  Sanaz Rismanchi; Orly Yadegar; Samad Muhammadnejad; Saeid Amanpour; Masoud Taghizadeh-Jahed; Ahad Muhammadnejad
Journal:  Biomed Rep       Date:  2014-07-08

3.  Mutation Screening of BRCA Genes in 10 Iranian Males with Breast Cancer.

Authors:  Atieh Zorrieh Zahra; Sepideh Kadkhoda; Farkhondeh Behjati; Fatemeh Aghakhani Moghaddam; Azadeh Badiei; Fereidoon Sirati; Hossein Afshin Alavi; Morteza Atri; Ramesh Omranipour; Elahe Keyhani
Journal:  Int J Mol Cell Med       Date:  2016-05-09

4.  Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.

Authors:  Frédérique Nguyen; Laura Peña; Catherine Ibisch; Delphine Loussouarn; Adelina Gama; Natascha Rieder; Anton Belousov; Mario Campone; Jérôme Abadie
Journal:  Breast Cancer Res Treat       Date:  2017-10-30       Impact factor: 4.872

Review 5.  Current biomarkers of canine mammary tumors.

Authors:  Ilona Kaszak; Anna Ruszczak; Szymon Kanafa; Kamil Kacprzak; Magdalena Król; Piotr Jurka
Journal:  Acta Vet Scand       Date:  2018-10-29       Impact factor: 1.695

6.  Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.

Authors:  Yoseop Kim; Soo-Hyeon Lee; Cheol-Jung Kim; Je-Jung Lee; Dohyeon Yu; Soomin Ahn; Dong-Jun Shin; Sang-Ki Kim
Journal:  BMC Vet Res       Date:  2019-10-14       Impact factor: 2.741

7.  Defucosylated mouse‑dog chimeric anti‑HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors.

Authors:  Hiroyuki Suzuki; Tomokazu Ohishi; Teizo Asano; Tomohiro Tanaka; Masaki Saito; Takuya Mizuno; Takeo Yoshikawa; Manabu Kawada; Mika K Kaneko; Yukinari Kato
Journal:  Oncol Rep       Date:  2022-07-20       Impact factor: 4.136

8.  Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine.

Authors:  Judit Fazekas; Irene Fürdös; Josef Singer; Erika Jensen-Jarolim
Journal:  Oncol Lett       Date:  2016-08-11       Impact factor: 2.967

9.  Comparative Analysis of the Development of Acquired Radioresistance in Canine and Human Mammary Cancer Cell Lines.

Authors:  Mark Gray; Arran K Turnbull; James Meehan; Carlos Martínez-Pérez; Charlene Kay; Lisa Y Pang; David J Argyle
Journal:  Front Vet Sci       Date:  2020-07-23

Review 10.  Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer.

Authors:  Mark Gray; James Meehan; Carlos Martínez-Pérez; Charlene Kay; Arran K Turnbull; Linda R Morrison; Lisa Y Pang; David Argyle
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.